Collaboration integrates Hongene’s advanced sgRNA synthesis technology with ReciBioPharm’s end-to-end CDMO services, streamlining gene editing drug development and accelerating time to market.
Hongene Biotech Corporation, a global leader in nucleic acid manufacturing, and ReciBioPharm, a leading advanced therapeutics CDMO services provider, have announced a strategic collaboration that will enhance gene editing drug manufacturing capabilities.
Hongene, renowned for its expertise in the nucleic acid manufacturing field, has recently pioneered a novel proprietary technology for sgRNA synthesis. This technique significantly diminishes impurities common in conventional production methods, thereby elevating product quality.
ReciBioPharm, with its state-of-the-art facilities near Boston, MA, is a provider of comprehensive CDMO services, including the integrated development, analytics, and GMP manufacturing of plasmid, mRNA, LNP, and sterile drug products. The company is also on the forefront of continuous manufacturing technology for mRNA-LNP products through its work with MIT and its grant from the FDA’s CBER office to provide faster readiness and reaction to new pandemic threats.
The strategic alliance between the two companies creates a unique solution for innovators in the gene editing field. ReciBioPharm will expand its service portfolio to include sgRNA manufacturing, utilizing Hongene’s innovative synthesis process, providing plasmid, mRNA, sgRNA, LNP, and fill-finish services in a single facility. This will streamline the entire development and manufacturing process, mitigating the logistical complexities of dealing with multiple CDMOs, and ultimately accelerating the path for drug development.
Vikas Gupta, President of ReciBioPharm, stated, "Our collaboration with Hongene Biotech marks an important step forward for ReciBioPharm, enabling us to offer comprehensive, seamless solutions in the rapidly evolving gene editing sector. The combination of Hongene’s high-quality raw materials and synthesis methods with our capabilities will provide our clients with an unmatched portfolio of services in this developing field."
Echoing the sentiment, Wei Jiang, CEO at Hongene Biotech, shares, "Our partnership with ReciBioPharm is set to redefine the manufacturing space for gene editing. Our cutting-edge sgRNA synthesis technology, combined with ReciBioPharm's expertise in end-to-end mRNA and drug product manufacture, promises to bring a unique solution that has significant value to the healthcare field."
